Navigation Links
Lexicon to Report Fourth Quarter and Year End 2012 Financial Results on February 21, 2013
Date:2/18/2013

THE WOODLANDS, Texas, Feb. 18, 2013 /PRNewswire/ -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), a biopharmaceutical company focused on discovering breakthrough treatments for human disease, will release its fourth quarter and year end 2012 financial results on Thursday, February 21, 2013 before the financial markets open.  Lexicon management will hold a conference call and webcast to discuss clinical development progress and financial results for fourth quarter and year end 2012 at 11:00 a.m. Eastern Time on February 21, 2013. 

The dial-in number for the conference call is 888-645-5875 (within the US/Canada) or 970-300-1531 (international).  The conference ID for all callers is 12316846.  Investors can access a live webcast of the call at www.lexpharma.com.  An archived version of the webcast will be available on the website through March 21, 2013.

About Lexicon
Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human disease.  Lexicon currently has multiple drug programs in clinical development for diabetes, irritable bowel syndrome, carcinoid syndrome and other indications, all of which were discovered by Lexicon's research team.  Lexicon has used its proprietary gene knockout technology to identify more than 100 promising drug targets.  Lexicon has focused drug discovery efforts on these biologically-validated targets to create its extensive pipeline of clinical and preclinical programs.  For additional information about Lexicon and its programs, please visit www.lexpharma.com.

Safe Harbor Statement
This press release contains "forward-looking" statements, including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellectual property, as well as other matters that are not historical facts or information.  All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements.  Information identifying such important factors is contained under "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2011, as filed with the Securities and Exchange Commission.  Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Lexicon Pharmaceuticals To Present At The Morgan Stanley Global Healthcare Conference
2. FDA Grants Lexicon Orphan Drug Designation for Telotristat Etiprate for the Treatment of Carcinoid Syndrome
3. Research and Markets: Cell Therapy - Technologies, Markets and Companies - 2013 Report
4. BioInformatics LLC New Market Report – Best Practices Guide for Advertising to Life Scientists
5. Pharmacyclics Reports Results for Six and Three Months Ended December 31, 2012
6. Palatin Technologies, Inc. Reports Second Quarter Fiscal Year 2013 Results; Teleconference and Webcast to be held on February 14, 2013
7. Neuland Labs Reports Third Quarter Fiscal Year 2013 Financial Results
8. Intraocular Lens (IOL) Market Worth $3.8 Billion By 2018 Say New Research Report at ReportsnReports.com
9. Regenerative Medicine and Stem Cells Market Deals Analysis in New Research Report at ReportsnReports.com
10. The MedZilla.com Employment Report for February, 2013: Health Care Sector Stimulates Job Growth Throughout the Recession
11. Cellular Therapy Market and Cord Blood Market 2013 Industry Research Report: MarketResearchReports.Biz
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... 23, 2017 , ... Today, researchers can fast-track sample collection ... and/or other biomarkers or SNPs of interest) using one, easy-to-collect saliva sample. With ... relationship between insulin and other relevant biomarkers can be extensively studied through a ...
(Date:2/23/2017)... and CARDIFF, UK (PRWEB) , ... February 22, ... ... society for optics and photonics , have been named Fellows of the Society ... scientific and technical contributions in the multidisciplinary fields of optics, photonics, and imaging ...
(Date:2/22/2017)... -- Scientists propose in Nature blocking a ... and maybe other lysosomal storage diseases as a possible ... therapies. An international research team led by ... included investigators from the University of Lübeck in ... The study was conducted in mouse models of lysosomal ...
(Date:2/22/2017)... Dublin - Research and Markets ... (Bio-Pesticide) Market-By Type, By Application, By End User, By Region, By ... ... Protection Market is forecasted to grow at a CAGR of 11.33% ... biological crop protection market is driven by the surging demand for ...
Breaking Biology Technology:
(Date:2/2/2017)... TOKYO , Feb. 1, 2017  Central ... innovative and meaningful advances worldwide, The Japan Prize ... Japan Prize, who have pushed the envelope in ... Information and Communication. Three scientists are being recognized ... outstanding achievements that not only contribute to the ...
(Date:1/26/2017)... 2017  Acuity Market Intelligence today released the ... Identity".  Acuity characterizes 2017 as a "breakout" year ... reflects a new understanding of the potential benefits ... digital identity are often perceived as threats to ... Principal of Acuity Market intelligence. "However, taken together ...
(Date:1/21/2017)... Research and Markets has announced the addition of the "Global ... ... recognition biometrics market to grow at a CAGR of 19.36% during ... scenario and the growth prospects of the global voice recognition biometrics ... the revenue generated from the sales of voice recognition biometrics including ...
Breaking Biology News(10 mins):